ArcherDX
ArcherDX is a leading molecular diagnostics company focused on advancing personalized genomic medicine through innovative next-generation sequencing (NGS) technology. The company develops and commercializes research and in vitro diagnostic (IVD) products, including companion diagnostics and cancer monitoring platforms, to enable precise and actionable cancer treatment and detection. With a robust technology platform based on patented Anchored Multiplex PCR (AMP™) chemistry, ArcherDX aims to democratize access to high-quality genomic testing, supporting community and regional healthcare settings.
Industries
Nr. of Employees
medium (51-250)
ArcherDX
2477 55th Street, Suite 202 Boulder, CO 80301
Patents
Methods for determining a nucleotide sequence contiguous to a known target nucleotide sequence
US-11781179-B2
View DetailsMethods of nucleic acid sample preparation for immune repertoire sequencing
US-10947582-B2
View Details
Methods for determining a nucleotide sequence contiguous to a known target nucleotide sequence
US-11781179-B2
View DetailsMethods of nucleic acid sample preparation for immune repertoire sequencing
US-10947582-B2
View DetailsProducts
Pan-solid tumor companion diagnostic (CDx)
A multi-gene companion diagnostic intended to identify actionable genomic alterations from tissue or blood specimens to support targeted therapy selection.
Personalized Cancer Monitoring (PCM) platform
A surveillance platform for recurrence monitoring and therapy response using high-sensitivity sequencing of ctDNA for minimal residual disease detection.
Targeted NGS research panels and kits
Research-use-only targeted NGS panels for applications including solid tumor research, blood cancer research, custom panels, and immuno-oncology.
Lyophilized assay reagent kits
Pre-formulated, lyophilized reagent kits intended to simplify handling and enable distributed laboratory deployment of sequencing assays.
Bioinformatics analysis software
Software for NGS data processing, variant and fusion calling, and report generation for targeted oncology assays; designed for integration with laboratory informatics systems.
Pan-solid tumor companion diagnostic (CDx)
A multi-gene companion diagnostic intended to identify actionable genomic alterations from tissue or blood specimens to support targeted therapy selection.
Personalized Cancer Monitoring (PCM) platform
A surveillance platform for recurrence monitoring and therapy response using high-sensitivity sequencing of ctDNA for minimal residual disease detection.
Targeted NGS research panels and kits
Research-use-only targeted NGS panels for applications including solid tumor research, blood cancer research, custom panels, and immuno-oncology.
Lyophilized assay reagent kits
Pre-formulated, lyophilized reagent kits intended to simplify handling and enable distributed laboratory deployment of sequencing assays.
Bioinformatics analysis software
Software for NGS data processing, variant and fusion calling, and report generation for targeted oncology assays; designed for integration with laboratory informatics systems.
Services
Design, development and validation support for targeted NGS assays including analytical validation planning and execution.
Provision and integration of bioinformatics pipelines for NGS data processing, variant interpretation and clinical report generation; integrations with LIMS and reporting tools.
Hands-on training and technical support to implement NGS panels, laboratory workflows and software in local laboratory settings.
Collaborative agreements with sequencing platform providers and informatics partners to develop, obtain regulatory approvals for, and commercialize IVD and companion diagnostic assays.
Design, development and validation support for targeted NGS assays including analytical validation planning and execution.
Provision and integration of bioinformatics pipelines for NGS data processing, variant interpretation and clinical report generation; integrations with LIMS and reporting tools.
Hands-on training and technical support to implement NGS panels, laboratory workflows and software in local laboratory settings.
Collaborative agreements with sequencing platform providers and informatics partners to develop, obtain regulatory approvals for, and commercialize IVD and companion diagnostic assays.
Expertise Areas
- Targeted NGS assay development for oncology
- Liquid biopsy and MRD assay development
- RNA-based fusion detection
- Bioinformatics and clinical reporting for genomics
Key Technologies
- Next-generation sequencing (NGS)
- Anchored multiplex PCR chemistry
- RNA-based fusion detection
- ctDNA (liquid biopsy) analysis
News & Updates
ArcherDX announced that the FDA granted Breakthrough Device Designation for its NGS device to detect NTRK gene fusions in cancer, utilizing proprietary AMP™ chemistry for sensitive detection in blood and tissue samples.
ArcherDX announced its participation in Cowen’s 2020 Liquid Biopsy Summit, with CEO Jason Myers presenting.
ArcherDX entered into a partnership with Illumina to develop IVD tests for targeted therapy and disease monitoring, to be run on Illumina’s NextSeq™ 550Dx System.
A collaboration enabling genomically defined treatments for underserved cancers.
The company announced the close of a $60 million financing to support its product portfolio and growth initiatives.
The company's NGS device for detecting NTRK gene fusions received FDA Breakthrough Device Designation.
ArcherDX announced that the FDA granted Breakthrough Device Designation for its NGS device to detect NTRK gene fusions in cancer, utilizing proprietary AMP™ chemistry for sensitive detection in blood and tissue samples.
ArcherDX announced its participation in Cowen’s 2020 Liquid Biopsy Summit, with CEO Jason Myers presenting.
ArcherDX entered into a partnership with Illumina to develop IVD tests for targeted therapy and disease monitoring, to be run on Illumina’s NextSeq™ 550Dx System.
A collaboration enabling genomically defined treatments for underserved cancers.
The company announced the close of a $60 million financing to support its product portfolio and growth initiatives.
The company's NGS device for detecting NTRK gene fusions received FDA Breakthrough Device Designation.